Multivariate GLS meta-analysis on ambient air pollution and congenital heart anomalies by Wang, Ni
  
 
 
 
 
 
 
 
Copyright 
by 
Ni Wang 
2014 
 
 
The Report Committee for Ni Wang 
Certifies that this is the approved version of the following report: 
 
 
Multivariate GLS meta-analysis on 
Ambient air pollution and Congenital heart anomalies 
 
 
 
 
 
 
 
APPROVED BY 
SUPERVISING COMMITTEE: 
 
 
 
Susan N. Beretvas 
John Hixon 
 
  
Supervisor: 
Multivariate GLS meta-analysis on 
Ambient air pollution and Congenital heart anomalies 
 
by 
Ni Wang, B.S.; M.S. 
 
 
Report 
Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Master of Science in Statistics 
 
 
The University of Texas at Austin 
May 2014 
 
 iv 
Acknowledgements 
 
At first, I would love to express the deepest appreciation to Professor Beretvas for 
her valuable suggestions on my report and for being supportive and encouraging during 
the past years. Moreover, I also want to thank Dr. Hixon for being my reader and sharing 
his knowledge with me during this semester. At last but not least, my appreciation goes to 
my family, I know you are always there whenever I need you, thank you for being so 
supportive and caring. Love you.   
 
 
 
  
 v 
Abstract 
 
Multivariate GLS meta-analysis on 
Ambient air pollution and Congenital heart anomalies 
 
Ni Wang, M.S.Stat 
The University of Texas at Austin, 2014 
 
Supervisor:  Susan N. Beretvas 
 
The effects of air pollutants CO, NO2, O3, PM10 and SO2 on congenital heart 
anomalies are represented by the odds ratio of each disease per unit increase in the 
concentration of each pollutant. In this study, the effects of air pollutants are summarized 
using multivariate GLS approach with correlation between outcomes being taken into 
account, where the correlations are sampled from uniform [-1,1]. Meta-analysis 
conducted here found no statistically significant increase in odds ratio of any disease.  
This result is different from what Vrijheid et al. 2011 suggested when correlation 
is not considered using the same set of data. The difference in conclusions from the two 
meta-analysis indicates that correlation between outcomes may play an important role 
when synthesizing effect sizes. Thus, before conduct meta-analysis, a thorough 
consideration about whether to incorporate the correlation in synthesizing should be 
given. 
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 1 
INTRODUCTION 
  Severe ambient air pollution happening in China has recently drawn attention 
worldwide. The World’s Health Organization (WHO) estimated that seven million people 
have died as a result of air pollution in 2012 and nearly six million of the deaths have 
been in South East Asia. Ambient air pollution is found to be mainly connected to 
cardiovascular disease which has become one of the biggest risk factor negatively 
impacting global health. More strikingly, it not only impacts the health of human beings 
today, but may also have a greater impact on human’s future.  
Animal toxicology literature suggests that adverse reproductive effects (Tsukue et 
al. 2001; Singh et al. 1988) and heritable gene mutations (Somers et al. 2002; Somers et 
al. 2004; Samet et al. 2004) can be produced by air pollution exposure. Outside the 
laboratory, the adverse effects of ambient air pollution on fetus and newborn from 
maternal prenatal exposure have been demonstrated in a growing number of 
epidemiology studies (Glinianaia et al. 2004; Maisoner et al. 2004; Sram et al. 2004; 
Vrijheid et al. 2011).  Thus, new concerns are rising. It has been suggested that air 
pollution may play a critical role in causing congenital anomalies (Ritz et al. 2010; 
Vrijheid et al. 2011). Congenital anomalies are a main cause of infant mortality and 
remain the leading cause of disability worldwide (Ritz et al. 2002) which affect about 1 in 
33 infants and result in approximately 3.2 million birth defect related disabilities every 
year. Congenital heart defects are the most common severe congenital anomalies, 
appearing in 4-8 of 1000 live births (van der Linde et al. 2013)   
Major air pollutants that are most frequently studied are carbon monoxide (CO), 
sulfur dioxide (SO2), nitrogen dioxide (NO2), Ozone (O3) and particulate matter 10 
(PM10). During the past few decades, several epidemiological studies have focused on the 
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association between the major air pollutants and congenital heart anomalies. However, 
their results are not consistent (Ritz et al. 2002; Gilboa et al. 2005; Rankin et al. 2009; 
Strickland et al. 2009; Hansen et al. 2009; Dolk et al. 2010; Dadvand et al. 2011a; 
Dadvand et al. 2011b). Only one meta-analysis focused on air pollution and risk of 
congenital heart anomalies has been found in the literature. It was published by Vrijheid 
et al. in 2011. In this meta-analysis, the authors found evidence for an effect of ambient 
air pollution on congenital cardiac anomaly risk. They reported that nitrogen dioxide 
(NO2) and sulfur dioxide (SO2) exposure were related to increase in risk of Coarctation of 
the aorta and Tetralogy of Fallot, and PM10 exposure was related to an increased risk of 
Atrial septal defects.  
When calculating the overall effect of each pollutant on a certain type of 
anomalies, the above meta-analysis did not consider the possible correlation between 
different types of congenital heart defects but treated them as independent effect sizes 
which may threaten the validity of the resulting conclusions. In the current meta-analysis, 
a new set of summary odds ratio were calculated with the correlations between different 
effect sizes were taken into account and Generalized least square (GLS) method was 
employed. 
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METHOD 
BASIC IDEAS OF META-ANALYSIS 
Different effect sizes are reported by different research papers for the same 
treatment but using different samples. Thus, it is difficult to tell what the true effect size 
might be for a certain treatment and a certain demographics. The major goal of a meta-
analysis is to provide the estimated overall effect by combining the results of individual 
studies taking into account the precision of the study. For studies which are more precise 
than others, more weight will be given to associated effect size estimate. Instead of 
computing simple mean of the effect sizes, weighted mean is computed, with more 
weight given to some studies and less weight given to the others (Cooper et al. 2
nd
 
edition). 
Multiple effect sizes within a study 
If a single effect size is reported by each study, the pooled effect is easily 
calculated by plug in the formula below: 
  ̅  
∑      
 
   
∑   
 
   
 (1) 
Where  ̅  is the synthesized effect size, it can be any type of effect sizes. The 
common types of them are standardized mean difference, correlation and natural 
logarithm of odds ratio. And    is weight being assigned to the corresponding effect size 
which is simply the inverse of the variance of that effect size. At last, n is the number of 
studies under investigation.  
For studies report multiple effect sizes, cases have to be treated differently.  
If the effect sizes are independent, for example, if the treatment effect (e.g., drug 
versus placebo) varies by gender, then the treatment effect can be reported separately for 
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male and for female. The key feature is that the subgroups are independent of each other, 
so that each provides unique information. For this reason, we can treat each subgroup as 
separate study.  
However, for some studies, the reported multiple effect sizes are not independent. 
For example, in the study of air pollution and congenital anomalies, for a specific 
pollutant, given CO, the effect sizes reported are the odds ratio of Coarctation of the aorta 
(CA), Tetralogy of Fallot (TF), and Atrial septal defects (ASD) for per 1ppm increase in 
CO. In this case, multiple measures yield more than one treatment versus control effect 
sizes. Because the effect sizes from the study share the same control group, the estimates 
of effect sizes are correlated. When synthesizing effect sizes from such studies, the 
possible dependency among effect sizes should be accounted for. In order to do this, 
correlations between effect sizes within a study has to be obtained (Cooper et al. 2
nd
 
edition, Gleser J et al. 1994, Raudenbush W et al. 1988, Timm H 1999, Dimitris 2011). 
MODELS FOR MULTIVARIATE META-ANALYSIS 
Multivariate methods for meta-analysis synthesis that recognize the correlation 
between estimated effect sizes within-study will be employed in this study (Cooper et al 
2
nd
 edition). There are two basic models used in multivariate meta-analysis, which 
include fixed effects model and random effects model. Fixed effects model assume that 
one true effect size are shared by all studies. The assumption is that variability in studies’ 
effect size estimates are solely a function of sampling error.  
On the other hand, random effects model allows the true effect sizes to vary 
across studies, based on the assumption that the potential moderators underlying would 
inevitably vary among studies and generate different true effect sizes. Under random 
effects model, the effect size of each available study can be conceived as an item drawn 
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from a random sample of all possible effect sizes. The variance under random effects 
model consists two components. One component is random effects variance which 
represents the variance that arises as a result of the sampling of studies, each having a 
unique effect size. Another component is the estimation variance which arises because of 
the finite sample of subjects each effect size is based upon (Hedges 1983, DerSimonian 
1986, Cooper et al. 2
nd
 edition). Both models for multiple outcomes will be introduced in 
detail below. To make it simple, bivariate model will be given as examples for both 
multivariate fixed effects and random effects model. 
Multivariate fixed effects meta-analysis    
The following contents are cited from Mavridis et al. 2011 unless specified.  
Suppose we obtain two estimate effect sizes yi1 and yi2 from each study i. In a 
fixed effects model, the study-specific estimated effect sizes follow a bivariate normal 
distribution. For odds ratio, in order to follow the normal distribution, it has to be 
converted to natural logarithm metric. 
 (
   
   
)    ((
  
  
)  (
   
 
        
        
   
 )) (0) 
Where μ=(     )' denotes the vector of means for each outcome,    is the 
correlation between outcome 1 and 2 within study i and the covariance matrix for study i 
is Si 
       (
   
 
        
        
   
 ) (3) 
Fixed effects model can be represented by matrix notation equivalently as 
         (4) 
where ei denotes a vector of random sampling error. 
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Multivariate random effects meta-analysis 
In random effects model, it assumes that both the overall variation and overall 
correlation come from two sources which are within-study and between-study. It suggests 
that 
 (
   
   
|
   
   
)    ((
   
   
)  (
   
 
        
        
   
 )) (5) 
where ө=( өi1,өi2)’ denotes the underlying study specific effect sizes which are also 
normally distributed as  
 (
   
   
)    ((
  
  
)  (
  
 
      
      
  
 )) (6) 
where is   
  the between-study variation for effect size 1 and   
  is the between-study 
variation for effect size 2. They are also known as heterogeneity or random effects 
variance. It is calculated based on method of moments suggested by Cooper et al. 2
nd
 
edition and other references (Hedges 1983; DerSimonian 1986).  
The between-study covariance matrix is Δ, which is 
   (
  
 
      
      
  
 ) (7) 
In random effects model, the overall variation is the sum up of within-study 
variance   
  and between-study variance Ʈi
2
. Overall correlation is the sum up of within-
study correlation and between-study correlation. Therefore, the overall covariance matrix 
for random effect model is 
 
    (    
 
        
        
   
 )  (
  
 
      
      
  
 )  (
  
     
 
               
               
  
     
 )       (8) 
Hence, generally the distribution of effect sizes under random effects model is the 
combining of equation 6 and 7 as shown below: 
 7 
 (
   
   
)    ((
  
  
)  (
  
     
 
               
               
  
     
 )) (9) 
Random effects model can be represented by matrix notation as follows: 
            (10) 
 
where δi is a vector of random effects associated with study i, δi~MVN(0,Δ) and ei is a 
vector of random sampling errors associated with study i, ei~MVN(0,Si). Thus the 
covariance matrix of yi is Δ+Si (Hedges 1998). 
Multivariate mixed effects meta-analysis 
If covariates are included in the model, we will have mixed effects model. With 
μ=xi* β, the model becomes:   
              (11) 
where Xi is a design matrix with observed covariate values for coefficients and ones for 
intercept, it also contains columns of ones and zeroes which indicate the membership of 
studies, and β is the vector of coefficients for each of the study (Hedges 1992). 
GLS METHODS FOR MULTIVARIATE META-ANALYSIS 
Assuming that you are interested in doing a multivariate meta-analysis with p 
outcomes, the parameters of interest in your study are the synthesized effect sizes. In this 
case, the uncertainty in the estimated effect sizes represented by the within-study 
covariance matrix and the between-study covariance matrix should be considered. 
Various methods exist for estimating such parameters, one of them are Generalized Least 
Square (GLS) method and this is the one will be employed in my study.  
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Supposing n studies are investigated, with p outcomes from each. Each outcome 
can be modeled by a regression model, and the regression models are correlated. The 
vector of effect sizes y is a np X 1 vector, where the first p elements are from study 1 
followed by p elements from next study etc. For fixed and random effects models, 
synthesized effect sizes are the parameters of interest, thus no covariates are added in the 
model. Design matrix X can be represented by combination of p x p identity matrix. S is 
the overall covariance matrix with each within study covariance matrix on diagonal. To 
simplify, n and p both equal to 2. Given no correlations exists between studies, X, y, and 
S can be represented below. 
   [
  
  
]  [
  
  
  
  
]           [
   
   
   
   
]  
   [
  
  
  
  
  
  
]  
[
 
 
 
 
   
         
           
 
                   
                   
    
                   
                   
   
         
           
 ]
 
 
 
 
 (12) 
The summary effect size estimated by GLS method is: 
  ̂                   (13) 
For fixed effects model, the covariance matrix S is as illustrated above in the 
example.  
When talking about random effects model, between-study covariance matrix Δ 
should also be taken into account. The new covariance matrix in random effects model 
are showing below, again assuming no correlations exist between studies. 
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 (14) 
 
The way of finding out between-study variance   
  is clearly described in 
reference (Cooper et al. 2
nd
 edition) and will not be discussed here. 
If covariates are added in random effects model, mixed effects model is 
constructed. Under this model, the estimates coefficients from GLS are given (Berkey et 
al. 1998, Becker BJ and Wu MJ 2007, Mavridis 2011).      
  ̂    
               (15) 
The value of covariates needs to be added to the design matrix X of random 
effects model in order to fit the mixed effects model. A simple example about how to 
build the design matrix for mixed effects mode is given below. 
Assuming the value of each covariate is: 
 
 Study 1 Study 2 
Outcome 1 0.5 0.5 
Outcome 2 1.3 0.9 
 
 
Table 2.1    Example giving for mixed effects model 
The new design matrix used for mixed effects model is: 
   [
      
      
      
      
]  
HOMOGENEITY TEST FOR MODEL SELECTION 
The decision about whether a fixed effects model or a random effects model is 
more appropriate is made based on the conclusion of homogeneity test.  
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Homogeneity test is an analysis of variance which tests for the degree of 
variability among effect sizes. The null hypothesis assumes that the specific effect size 
estimates are homogeneous across studies, indicating the variability among them is 
purely from sampling error. If null hypothesis can’t be rejected, a fixed effects model 
should be used, otherwise heterogeneity of effect sizes between studies should be taken 
into account and random effects model should be applied.  
After effect sizes are estimated by fixed effects model, the Q statistics from 
homogeneity test can be calculated by equation 16: 
    
                  (16) 
where μ denotes the vector of summarized effect sizes. 
Q statistics follows a χ2 distribution, with degree of freedom equals to number of 
effect sizes included minus number of effect sizes estimated or number of outcomes. It 
tells whether that model specification is statistically adequate. Thus, it can be used as a 
diagnostic statistics (Dankmar et al. 2002; Pierre et al. 1989; Joseph F 1991). If the Q 
statistics is greater than the critical value for a given degree of freedom at α =0.05, the 
null hypothesis is rejected and random effects model applies.  
When between-study correlation is considered, the covariance matrix for random 
effects model would be the one shown in equation 9. However, if the between-study 
correlation is not considered, then covariance matrix used for random effects model 
should be the one shown in equation 14.  
The basic steps of model selection are summarized as follows: 
1. Obtain synthesized effect sizes from fixed effects  
2. Carry out homogeneity test 
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3. Apply random effects model to obtain new set of pooled effect sizes if null 
hypothesis of homogeneity test is rejected, otherwise report effect sized generated 
from fixed effects model 
4. Perform homogeneity test with effect sizes given by random effects model 
5. Employ mixed effects model with covariate added if null hypothesis of 
homogeneity test is rejected and report the coefficients obtained from mixed 
effects model as well as report pooled effect sized synthesized by random effects 
model. 
The detail in calculating Q statistic is provided by Cooper et al. 2
nd
 edition and 
won’t be discussed here. 
ESTIMATION OF UNKNOWN WITHIN-STUDY COVARIANCE MATRIX USING SIMULATION 
A crucial feature in multivariate meta-analysis is to obtain the possible correlation 
between outcomes and the incorporation of this correlation into a statistical model. With 
original data, variance and covariance can be directly estimated. However, in meta-
analyses of aggregated data, it is impossible to obtain the correlation between outcomes. 
To figure that out, one suggestion is to obtain the possible correlation from external 
research papers (Mavridis et al. 2011). Unfortunately, it is infeasible in my case. Instead, 
a simulation method is applied in this study. More specifically, assuming that the 
correlation ρ is a random variable that follows a uniform [-1,1] distribution. Draw ρ from 
that distribution for 10,000 times. Thus, 10,000 within-study covariance matrices for each 
study will be generated with the covariance terms obtained from the sampled ρs. Then 
10,000 overall covariance matrices for multivariate meta-analysis will then be obtained 
by assigning each within-study covariance matrix on diagonal.   
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With the simulated ρ and corresponding covariance matrix, the distribution of 
summary effect size for each outcome can be obtained. From which the estimated mean 
of each effect size and its 95% confidence interval (95% CI) are obtained.  
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DATA ANALYSIS AND RESULT 
SOURCE OF DATA 
In this study, I am interested in summarizing the odds ratio (OR) of a certain type 
of congenital heart anomalies per unit increase in continuous pollutant concentration 
assuming that the natural logarithm of odds ratio is linearly correlated with the 
concentration of air pollutant. The correlation between effect sizes within-study is 
considered in my model, but not that of between-study. The studies included in this meta-
analysis were conducted by researchers all over the world across last decades, from 
which it is reasonable to assume independence of the studies’ results. Therefore, the 
covariance matrix in my study is similar to equation 14 provided in the chapter of 
method. 
There are two difficulties in summarizing correlated effect sizes directly from 
original papers. The first one is that the unit of measurement for each pollutant is 
different, thus it is not appropriate to combine the odds ratio for per unit increase of a 
certain pollutant directly. The second one is that congenital heart anomalies are 
categorized and named differently in different papers. Thanks to Vrijheid etc., they 
figured both out by unifying the unit of each pollutant and converting the corresponding 
effect sizes to same metric as well as listing the selected effect sizes commonly provided 
by included studies. Thus the effect sizes investigated in my study are solely taken from 
the appendix 2 from the supplements of Vriheid et.al 2011. 
The unified units they converted to is 10μg/m3 for PM10, 10 ppb for O3 and NO, 
1 ppm for CO and 1 ppb for SO2. And the common congenital heart anomalies they 
summarized are Atrial septal defects (ASD), Conotruncal defects (CD), Ventricular septal 
defects (VSD), Coarctation of the aorta (CA) and Tetralogy of Fallot (TF).  
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In the current meta-analysis, I summarized the effects of each air pollutant on a 
couple of congenital heart anomalies using GLS multivariate meta-analysis with R 
statistical software. The results are shown below. 
THE EFFECTS OF CO  
The effects of CO on 3 diseases are examined from 5 studies. The effect size 
studied is the odds ratio of a specific disease per unit increase in the concentration of CO. 
The examining diseases are Atrial septal defects (ASD), Ventricular septal defects (VSD) 
and Conotruncal defects (CD). Among the 5 studies, 4 of them reported the odds ratio of 
all the 3 outcomes and 1 of them only contained odds ratio of the first two outcomes. 
Such studies have situations where certain diseases are not measured. However, such 
“missingness” is designed on purpose, it is not the kind of missing data usually concerned 
in literature (Little and Rubin 1987, Little and Schenker 1994) and can be dealt with 
method described in Becker 1990 and Powers and Rock 1998, 1999. One thing need to 
keep in mind is that the odds ratio cannot be used in calculation directly. It needs to be 
converted to its natural logarithm metric in order for being used in meta-analysis 
involved calculation. Thus all the values in matrix below are in natural logarithm metric 
unless indicated. 
Fixed effects model 
First, the summarized effect sizes are estimated from fixed effects model. 
The design matrix X, vector of effect sizes y and covariance matrix S1 through S5 for 
fixed effects model are shown below. 
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With 5 studies in total, there are 5 within-study covariance matrices. The within-
study covariance matrices for study 1 through 5 are: 
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] 
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 ] 
The big covariance matrix S for multivariate meta-analysis is a 14 x 14 matrix as 
follows: 
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where ρi~ uniform[-1,1] , it is sampled 10,000 times, thus 10,000 big covariance matrix is 
generated, from which, 10000 summarized effect sizes for each outcome are calculated 
using equation 13 given before : 
  ̂    
               (13) 
The above variance covariance matrix can also be represented as following for 
simplicity. 
  [
    
   
    
]                
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Distribution of lnOR  
From simulation, the distribution of natural logarithm of each outcome generated 
from fixed effects model is obtained. Three diseases ASD, VSD and CD are named as 1, 
2 and 3 in the following figures for convenient. 
 
 
Figure 3.1  Distribution of lnOR of CO on each outcome generated from fixed effects 
model. 
Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 0.565 [0.014, 29.346]  
VSD 1.071 [0.055, 29.781] 
CD 1.508 [0.006, 90.051] 
Table 3.2.  Estimated effect size of CO for each disease and corresponding 95%  
confidence interval generated from fixed effects model 
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Homogeneity test 
With 10,000 ρs sampled from uniform [-1,1], 10000 homogeneity tests are carried 
out. For each homogeneity test, the number of effect sizes provided is 14 and the number 
of effect sizes estimated is 3, thus the degree of freedom (df) is 11. The critical Q 
statistics is 19.695 with df equals to 11 and α is 0.05. Comparing each Q statistics from 
10,000 homogeneity tests with the critical value 19.695, 7965 of the datasets led to 
rejection of the null hypothesis. The proportion of rejection is then 79.56%. Thus random 
effects model should be applied. 
Random effects model 
The estimated between-study variance   
  for each outcome is calculated based 
on method of moments mentioned before. Positive between-study variance suggests the 
existing of random effects among studies. The calculation of estimated between-study 
variance is thoroughly discussed in the reference mentioned above and all the formulas 
associated can be found there.  
Among the 3 diseases, only disease 3 has positive between-study variance. This 
suggests that the random effects between-study is mainly from disease 3. The between-
study variance for disease 3 is added to the original covariance matrix and the variance 
for disease 3 in each study is now replaced by new variance:      
     
 . Within-
study covariance matrix for study 5 doesn’t change since it doesn’t contain effect size 
from disease 3. 
The new within-study covariance matrices for study 1 through 4 as are listed 
below: 
  
  [
   
                     
             
           
                      
     
 
]  
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  [
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  [
   
                     
             
           
                      
     
 
] 
 
  
  [
   
                     
             
           
                      
     
 
] 
Again, the new big covariance matrix can be represented as following for 
simplicity. 
   [
     
   
    
]                 
Using GLS method, the distribution of each estimated effect size as well as the 
95% CI of them are obtained and pasted below. 
Distribution of lnOR 
 
Figure 3.2  Distribution of lnOR of CO on each outcome generated from random effects 
model 
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Figure 3.2 continued  
Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 0.699 [0.248,  2.527] 
VSD 0.893 [0.383,  2.818] 
CD 0.024 [0.005, 141.530] 
Table 3.2  Estimated effect size of CO for each disease and corresponding 95%  
confidence interval generated from random effects model. 
Homogeneity test 
Homogeneity test is conducted with summarized effect sizes obtained from 
random effects model. Out of 10,000 tests, 9478 of them are rejected. Indicating the 
variation among effect sizes for each outcome cannot be explained by sampling error and 
random effects. Therefore, covariates need to be added to the model in order to interpret 
the variation. The value of covariate incorporated is the mean concentration of CO from 
each study. With covariate considered, the model becomes mixed effects model and will 
estimate the corresponding coefficients by applying GLS method. 
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Mixed effects model 
The covariance matrix used in mixed effects model is the same as that of the 
random effects model. However, new design matrix is constructed with the concentration 
of CO added. 
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The mixed effects models are constructed for this multivariate meta-analysis. In 
the model, 2 coefficients for each outcome are estimated. One of the estimated 
coefficients is the intercept and the other one is coefficient for covariate which is the 
mean concentration of CO in this case. From equation 15 listed previously, the 
coefficients can be obtained. 
  ̂    
               (15) 
Point estimate and confidence interval 
 β0 95% CI of β0 β1 95% CI of β1 
ASD -0.786 [-3.375, 1.943] 0.442 [-0.991,  1.726] 
VSD 0.169 [-0.783, 0.994] -0.032 [-0.660,  0.544] 
CD -0.400 [-4.602, 3.750] -0.159 [-1.480,  1.309] 
Table 3.3  Estimated effect size of CO for each disease and corresponding 95% 
confidence interval generated from mixed effects model 
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THE EFFECTS OF NO2 
Models, related matrices and procedures of analysis about CO were shown in 
detail above. To avoid redundancy, I will not list the detail of analysis about other 
pollutants since they are following the same way as that of CO. Instead, I will only show 
the result of meta-analysis for the rest of the pollutants.   
The effects of NO2 on 4 diseases from 5 studies are analyzed. The 4 diseases 
discussed are ASD, VSD, Coarctation of the aorta (CA) and Tetralogy of Fallot (TF). 
These four diseases are renamed as 1, 2, 3 and 4 for conveniently shown in figures below. 
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Fixed effects model 
Distribution of lnOR  
 
 
Figure 3.4  Distribution of lnOR of NO2 on each outcome generated from fixed effects 
model. 
Point estimate and confidence interval 
 Mean of OR 95% CI of OR 
ASD 0.982 [0.024, 43.146] 
VSD 1.512 [0.185, 7.746] 
CA 1.155 [0.043, 21.234] 
TF 1.809 [0.056, 33.957] 
Table 3.4  Estimated effect size of NO2 for each disease and corresponding 95% 
confidence interval generated from fixed effects model 
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Homogeneity test 
Homogeneity test is carried out using the summarized effect size synthesized 
from fixed effects model. With 10,000 ρs sampled from uniform [-1,1], 10,000 
homogeneity tests are performed. For each homogeneity test, the total number of effect 
sizes provided by the including studies is 16 and the number of effect sizes estimated is 4, 
thus the degree of freedom (df) is 12. The critical Q statistics is 21.026 with df equals to 
12 and α is 0.05. Comparing each Q statistics generated from 10,000 homogeneity tests 
with the critical value 21.026, 5098 of the datasets led to rejection. The proportion of 
rejection is then 50.98%. Hence random effects model should be employed. 
Random effects model 
The between-study variance for each disease is calculated. However, none of 
them has positive between-study variance. This suggests that the variation is not from 
random effects. So the concentration of NO2 is incorporated into the model to test if the 
variability could be explained by this covariate. 
Weighted regression model 
The mean concentration of NO2 from each study is added to the design matrix of 
fixed effects model as covariate. Using this new design matrix, weighted linear regression 
model is created. The parameters this model estimated are the coefficients for covariate 
and intercept in the linear regression model. 
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Point estimate and confidence interval 
 β0 95% CI of β0 β1 95% CI of β1 
ASD 0.782 [-2.018, 2.510] -0.719 [-3.283, 3.248] 
VSD 0.038 [-1.045, 1.294] 0.233 [-1.673, 1.787] 
CA -0.218 [-1.798, 2.075] 0.029 [-2.413, 2.256] 
TF -0.163 [-2.516, 1.658] -0.275 [-2.101, 3.165] 
Table 3.5  Estimated coefficients and their 95% confidence intervals obtained from 
weighted regression model 
THE EFFECTS OF O3 
The effects of O3 on 3 diseases from 5 studies are summarized here. The 
examining diseases are ASD, VSD and Conotruncal defects (CD) and are renamed as 1, 2 
and 3 for simplicity discussed later. 
Fixed effects model 
Distribution of lnOR  
 
Figure 3.6  Distribution of lnOR of O3 on each outcome generated from fixed effects 
model. 
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Figure 3.6 continued. 
Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 1.083 [0.285, 4.316] 
VSD 0.975 [0.428, 1.990] 
CD 1.106 [0.313, 3.370] 
Table 3.6   Estimated effect size of O3 for each disease and its 95% confidence interval 
obtained from fixed effects model 
Homogeneity test 
A Homogeneity test is conducted using the summarized effect size synthesized 
from fixed effects model. With 10,000 ρs sampled from uniform [-1,1], 10,000 
homogeneity tests are carried out. For each homogeneity test, the total number of effect 
sizes under investigation is 14 and the number of effect sizes estimated is 3, thus the 
degree of freedom (df) is 11. The critical Q statistics is 19.695 with df equals to 11 and α 
is 0.05. Comparing each Q statistics from 10,000 homogeneity tests with the critical 
value1 9.695, 6270 of the datasets led to rejection of the null hypothesis. The proportion 
of rejection is 62.7%. Thus the random effect model should be applied.   
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Random effects model 
The between-study variance for each disease is calculated. Only disease 2 has 
positive between-study variance. This suggests that the between-study variation is from 
disease 2. So new covariance matrix is constructed as described above and summarized 
effect sizes are estimated by random effects model using the new covariance matrix 
Distribution of lnOR 
 
 
Figure 3.7  Distribution of lnOR of O3 on each outcome generated from random effects 
model. 
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Point estimate and confidence interval 
 Mean OR 95%CI of OR 
ASD 1.071 [0.417, 2.681] 
VSD 0.933 [0.424, 1.980] 
CD 1.107 [0.584, 2.104] 
Table 3.7   Estimated effect size of O3 for each disease and its 95% confidence interval 
obtained from random effects model 
Homogeneity test 
Homogeneity test is also carried out using the summarized effect size provided by 
random effects model. Out of 10000 tests, 5685 are rejected. Suggests the variation 
cannot only be explained by sampling error and random effects. Therefore, in order to 
finding the source of variability, the mean concentration of O3 from each study is added 
to the random effects model as covariate to create mixed effects model. 
Mixed effects model 
Mixed effects models are constructed for this multivariate meta-analysis. In the 
model, 2 coefficients for each outcome are estimated. One of the estimated coefficients is 
the intercept and the other one is coefficient for covariate which is the mean 
concentration of O3 in this case. From equation 16, the coefficients can be obtained. 
Point estimate and confidence interval 
 β0 95% CI of β0 β1 95% CI of β1 
ASD -0.015 [-3.305, 2.001] 0.024 [-0.640, 1.150] 
VSD -1.274 [-2.592, 2.165] 0.403 [-0.710, 0.807] 
CD 1.528 [-3.155, 3.890] -0.526 [-1.339, 1.106] 
Table 3.8  Estimated coefficients and their 95% confidence intervals generated by 
mixed effects model 
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THE EFFECTS OF PM10  
The effects of PM10 on 4 diseases from 5 studies are summarized. These four 
diseases are ASD, Ventricular, Coarctation of the aorta (CA) and Tetralogy of Fallot 
(TF). As shown above, the four diseases are renamed again as 1, 2, 3 and 4. 
Fixed effects model 
Distribution of lnOR 
 
 
Figure 3.9  Distribution of lnOR of PM10 on each outcome generated from fixed effects 
model. 
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Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 1.089 [0.118, 12.692] 
VSD 1.176 [0.373,  3.347] 
CA 1.367 [0.245,  6.406] 
TF 1.273 [0.076, 16.054] 
Table 3.9   Estimated coefficients and their 95% confidence intervals generated by 
fixed effects model 
Homogeneity test 
Homogeneity test is performed using the summarized effect size generated by 
fixed effects model. With 10,000 ρ sampled from uniform [-1,1], 10,000 homogeneity 
tests are performed. For each homogeneity test, the number of effect sizes provided is 16 
and the number of effect sizes estimated is 4, thus the degree of freedom (df) is 11. The 
critical Q statistics is 21.026 with df equals to 12 and α is 0.05. Comparing each Q 
statistics from 10000 homogeneity tests with the critical value 21.026, 5870 of the 
datasets led to rejection of the null hypothesis. The proportion of rejection is 58.7%. Thus 
random effect model should be applied. 
Random effects model 
The between-study variance for each disease is calculated. Only disease 2 has 
positive between-study variance. This suggests that the between-study variation is from 
disease 2. So new covariance matrix is constructed as described above and summarized 
effect sizes are estimated by random effects model using the new covariance matrix. 
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Distribution of lnOR 
 
 
Figure 3.10  Distribution of lnOR of PM10 on each outcome generated from random 
effects model. 
Point estimate and confidence interval  
 Mean OR 95% CI of OR 
ASD 1.123 [0.190, 6.971] 
VSD 0.972 [0.337, 3.186] 
CA 1.278 [0.389, 3.856] 
TF 1.357 [0.140, 7.326] 
Table 3.10  Estimated effect size of PM10 for each disease and its 95% confidence 
interval given by random effects model  
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Homogeneity test 
Homogeneity test is also carried out using the summarized effect size generated 
from random effects model. Out of 10000 tests, 6708 of them are rejected. Suggesting the 
variation cannot only be explained by random error and systematic difference between 
studies. Therefore, covariates need to be added to the model in order to interpret the 
variation. Mean concentration of PM10 from each study is added to the random effects 
model as covariate to create mixed effects model.   
Mixed effects model 
Mixed effects model is constructed for this multivariate meta-analysis. In the 
model, 2 coefficients for each outcome are estimated. One of the estimated coefficients is 
the intercept and the other one is coefficient for covariate which is the mean 
concentration of PM10 in this case. 
Point estimate and confidence interval  
 β0 95% CI of β0 β1 95% CI of β1 
ASD -0.039 [-1.066 0.880] 0.113 [-0.544 0.845] 
VSD -0.341 [-0.866 0.406] 0.171 [-0.367 0.582] 
CA -0.220 [-1.461 0.937] 0.186 [-0.483 0.945] 
TF -0.22428336 [-1.671, 1.006] 0.115 [-0.740, 1.099] 
Table 3.11  Estimated coefficients and their 95% confidence intervals from mixed 
effects model 
THE EFFECTS OF SO2  
The effects of SO2 on 4 diseases from 6 studies are summarized. The four 
diseases are ASD, VSD, CA and TF. As before, they are renamed as 1, 2, 3 and 4. 
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Fixed effects model 
Distribution of lnOR  
 
 
Figure 3.12  Distribution of lnOR of SO2 on each outcome generated from fixed effects 
model. 
Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 1.157 [0.517,  1.989] 
VSD 1.019 [0.669,  1.443] 
CA 0.881 [0.456,  2.281] 
TF 1.071 [0.525,  1.915] 
Table 3.12  Estimated effect size of SO2 for each disease and its 95% confidence 
interval given by fixed effects model  
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Homogeneity test 
As described above, 10,000 homogeneity tests are carried out. For each 
homogeneity test, the number of effect sizes provided is 20 and the number of effect sizes 
estimated is 4, thus the degree of freedom (df) is 16. The critical Q statistics is 26.296 
with df equals to 16 and α is 0.05. Comparing each Q statistics generated from 10,000 
homogeneity tests with the critical value 26.296, 6536 of the datasets led to rejection of 
the null hypothesis. The proportion of rejection is 65.36%. Therefore, random effect 
model should be applied. 
Random effects model 
The between-study variance for each disease is calculated. Only disease 3 has 
positive between-study variance. This suggests that the between-study variation is from 
disease 3. So new covariance matrix is constructed as described above and summarized 
effect sizes are estimated by applying random effects model using the new covariance 
matrix.   
Distribution of lnOR  
 
Figure 3.13  Distribution of lnOR of SO2 on each outcome generated from random     
effects model. 
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Figure 3.13 continued. 
Point estimate and confidence interval 
 Mean OR 95% CI of OR 
ASD 0.951 [0.581,  1.766] 
VSD 1.051 [0.751,  1.402] 
CA 0.941 [0.438,  2.112] 
TF 0.997 [0.567,  1.871] 
Table 3.13  Estimated effect size of SO2 for each disease and its 95% confidence 
interval given by random effects model 
Homogeneity test 
Homogeneity test is also carried out using the summarized effect size generated 
from random effects model. Out of 10000 tests, 6626 of them are rejected. Suggesting the 
variation cannot only be explained by random error and systematic difference between 
studies. Therefore, covariates need to be added to the model in order to interpret the 
variation. The mean concentration of SO2 from each study is added to the random effects 
model as covariate to create mixed effects model. 
Mixed effects model 
The mixed effects model is constructed for this multivariate meta-analysis. In this 
model, 2 coefficients for each outcome are estimated. One of the estimated coefficients is 
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the intercept and the other one is the coefficient for covariate which is the mean 
concentration of SO2 in this case. 
Point estimate and confidence interval 
 β0 95% CI of β0 β1 95% CI of β1 
ASD -0.118   [-1.669, 1.628] 0.012 [-0.176, 0.185] 
VSD 0.063   [-0.392, 0.512] -0.011 [-0.068, 0.050] 
CA 0.111   [-1.151, 1.442] -0.020 [-0.199, 0.159] 
TF 0.077   [-0.951, 1.070] -0.009 [-0.125, 0.112] 
Table 3.14  Estimated coefficient and its 95% confidence interval given by mixed 
effects model 
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CONCLUSION 
The effects of air pollutants CO, NO2, O3, PM10 and SO2 on congenital heart 
anomalies are represented by the odds ratio of each disease per unit increase in the 
concentration of each pollutant. The effect was summarized by fixed effects model for 
NO2 and random effects model for the rest of pollutants using multivariate GLS 
approach with correlation sampled from uniform [-1,1]. Moreover, the coefficients in 
mixed models which measure the linear relationship between the concentration of each 
pollutant and the risk of getting a disease were also reported in this analysis. Based on the 
result pasted above, none of the odds ratios significantly differs from 1. Therefore, my 
conclusion is that when correlation between outcomes is considered, the summarized 
effect sizes synthesized by GLS approach suggested that air pollutants didn’t have effects 
on the occurrence of congenital heart anomalies.   
When talking about coefficients in mixed models, all of them contained 0 in their 
95% CI, which may suggest that there is no linear relationship between the concentration 
of air pollutants and the natural logarithm of the odds ratio of congenital heart anomalies. 
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DISCUSSION 
The summarized effect sizes obtained by multivariate GLS method in my study 
are different from those provided by Vrijheid etc 2011 in their meta-analysis. They 
suggested that NO2 and SO2 exposures were related to increase in risk of Coarctaion of 
the aorta and Tetralogy of Fallot. However, from the meta-analysis I conducted, none of 
the exposure to any air pollutants seems to be related to the risk of any congenital heart 
anomalies. The biggest difference between the meta-analysis Vrijheid etc conducted and 
mine is that they didn’t consider the correlation between different outcomes within a 
study and used univariate meta-analysis method in analyzing their data. In my study, the 
correlations between outcomes were considered and multivariate GLS approach was 
applied. The difference in conclusions from two meta-analysis suggests that the 
incorporation of correlations between outcomes within a study can make a big difference 
when summary effect sizes are synthesized. Therefore, before any suggestion is made, 
thorough consideration about whether the correlation should be incorporated should be 
given.  
The 95% CI of all of the reported coefficients from the mixed models I 
constructed contains 0. However, I won’t say that there is no linear relationship between 
the concentration of air pollutant and the risk of heart anomalies. Simply because only 4 
or 5 studies are used in estimating the parameters from the mixed linear regression 
model, thus the power is not high enough to give a meaningful conclusion. To make 
accurate estimations on the coefficients, more studies would be included in the mixed 
model. 
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